ALX Oncology Stock Forecast
NASDAQ: ALXOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ALXO analyst consensus
Consensus (7 analysts)
none
Avg. price target
$4.60+268.00%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering ALX Oncology (2026-10-08), 6 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $4.60, with a high estimate of $6.00 and a low estimate of $4.00. The average target implies upside of 268.0% from the current price of $1.25.
The spread between the highest and lowest targets is 50.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALXO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 14% |
| Buy | 5 | 71% |
| Hold | 1 | 14% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $4.00 | +220.00% |
| Average target | $4.60 | +268.00% |
| High target | $6.00 | +380.00% |